Finland · Delayed Price · Currency is EUR Orion Oyj Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw strong growth across all divisions, with net sales up 18% and operating profit up 47% year-over-year. Upgraded full-year guidance reflects robust performance, especially in Innovative Medicines, and reduced downside risk from US tariffs.
-
Strong growth is driven by innovative oncology medicines, especially Nubeqa, with robust financial targets through 2028. Expansion into the US and Asia-Pacific, a diversified pipeline, and a flexible dividend policy support long-term global ambitions.
Fiscal Year 2025
-
Record 2025 results driven by Nubeqa milestone, strong growth across all divisions, and robust R&D progress. 2026 guidance anticipates higher sales, profit, and continued investment in pipeline and capacity. Dividend of €1.80 per share proposed.
-
Nubeqa drove record royalties and strong growth in innovative medicines, while generics and consumer health also performed well. Guidance was narrowed as year-end visibility improved, with R&D and U.S. pricing remaining key uncertainties.
-
Q2 2025 saw strong growth across all divisions, with net sales up 27% and operating profit up 59%, driven by innovative medicines and Nubeqa royalties. Updated guidance reflects continued momentum but maintains a wide range due to uncertainties in royalties, R&D timing, and market factors.
-
Achieved key financial targets ahead of schedule and set ambitious growth plans through geographic expansion, portfolio transformation, and increased R&D investment. Focus areas include innovative medicines, branded products, generics, and animal health, with robust financial discipline and readiness for strategic acquisitions.
-
Q1 2025 saw 15% net sales and 39% operating profit growth, led by innovative medicines and strong Nubeqa sales. Guidance for the year remains unchanged, with ongoing R&D expansion and a new phase III project for Levosimendan.
-
Strong growth is driven by geographic expansion, innovative oncology products, and a diversified portfolio. Nubeqa has reached blockbuster status, and the pipeline includes promising oncology and insomnia drugs. Financial targets through 2028 emphasize sustained growth and shareholder returns.
Fiscal Year 2024
-
2024 saw nearly 30% sales growth, driven by Nubeqa and milestone payments, with strong cash flow and a 33% rise in operating profit. 2025 guidance reflects Nubeqa's growing impact, wider ranges due to R&D and FX uncertainty, and no major milestones expected. Nubeqa now represents 34% of revenue.
-
Q3 saw robust growth, boosted by EUR 130 million in milestone payments and strong sales from Nubeqa, Easyhaler, and Animal Health. Despite project terminations and write-downs, guidance for 2024 remains unchanged, with R&D resources shifting to new oncology and biologics projects.
-
Q2 and H1 2024 delivered strong growth in net sales and operating profit, led by Nubeqa and Easyhaler, with improved cash flow and upgraded full-year guidance. Key milestones include a major MSD license deal and positive Nubeqa phase 3 results.